Albumin for CSA-AKI
Trial question
What is the role of albumin for reducing cardiac surgery-associated AKI in patients scheduled for cardiac surgery with cardiopulmonary bypass?
Study design
Single center
Double blinded
RCT
Population
Characteristics of study participants
35.0% female
65.0% male
N = 248
248 patients (86 female, 162 male).
Inclusion criteria: patients scheduled for cardiac surgery with cardiopulmonary bypass.
Key exclusion criteria: allergy to human albumin; receipt of iodinated contrast in the 7 days before surgery; pregnancy.
Interventions
N=126 albumin (albumin 4% and a crystalloid solution [Viaflo Plasma-Lyte®]).
N=122 crystalloid solution (crystalloid solution alone [Plasma-Lyte®]).
Primary outcome
Cardiac surgery-associated acute kidney injury
29.3%
31.2%
31.2 %
23.4 %
15.6 %
7.8 %
0.0 %
Albumin
Crystalloid
solution
No significant
difference ↔
No significant difference in cardiac surgery-associated AKI (29.3% vs. 31.2%; OR 0.91, 95% CI 0.53 to 1.58).
Secondary outcomes
Significant increase in use of vasodilators (23% vs. 10%; RR 2.3, 95% CI 0.34 to 4.26).
Conclusion
In patients scheduled for cardiac surgery with cardiopulmonary bypass, albumin was not superior to crystalloid solution with respect to cardiac surgery-associated AKI.
Reference
Jordi Miralles Bagán, Laura Parrilla Quiles, Pilar Paniagua Iglesias et al. The Potential Role of Albumin in Reducing Cardiac Surgery-Associated Acute Kidney Injury: A Randomized Controlled Trial. J Cardiothorac Vasc Anesth. 2025 Feb;39(2):453-460.
Open reference URL